Aerie Pharma (AERI) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aerie Pharmaceuticals Reports Year End 2015 Financial Results and Provides Business Update
March 1, 2016 4:01 PM EST- Company on Track to File NDA in 3Q 2016 for RhopressaTM (netarsudil ophthalmic solution) 0.02% -
Conference Call and Webcast Today, March 1, at 5:00 p.m. ET
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and year ended December 31, 2015, along with a general business update.
Aerie Highlights
... More